Cell Lines

PC3 PIP

PSMA-positive prostate cancer cell line.

$300 per line.

Cost

References:

A PSMA-Targeted Theranostic Agent for Photodynamic Therapy.

Chen Y, et al. J Photochem Photobiol B 2018.

PMID 28063300

Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.

Nimmagadda S, et al. J Nucl Med 2018.

PMID 29025989

PC3 flu

PSMA-negative prostate cancer cell line.

$300 per line.

Cost

References:

A PSMA-Targeted Theranostic Agent for Photodynamic Therapy.

Chen Y, et al. J Photochem Photobiol B 2018.

PMID 28063300

Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.

Nimmagadda S, et al. J Nucl Med 2018.

PMID 29025989

CHO-hPD-L1

CHO cell line stably expressing human PD-L1.  

$300 per line.

Cost

References:

PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG, et al. Bioconjug Chem 2016. Among authors: Nimmagadda S. PMID 27458027 Free PMC article.


Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Chatterjee S, et al. Biochem Biophys Res Commun 2017. Among authors: Nimmagadda S. PMID 28025143 Free PMC article.

 

Peptide-Based (68)Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
De Silva RA, et al. Mol Pharm 2018. Among authors: Nimmagadda S. PMID 30037229 Free PMC article.

 

Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Kumar D, et al. J Clin Invest 2019. Among authors: Nimmagadda S. PMID 30457978 Free PMC article.

 

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.

Chatterjee S, et al. Oncotarget 2016. Among authors: Nimmagadda S. PMID 26848870 Free PMC article.

Material Request

The Precision Medicine Resource Center offers a variety of resources and materials available for researchers to utilize. Information about available materials and how to request them can be found below.